Abstract OBJECTIVE In this study, KBP-042, a dual amylin- and calcitonin-receptor agonist, was investigated as a treatment of obesity and insulin resistance in five different doses (0.625 µg/kg-10 µg/kg) compared with saline-treated and pair-fed controls. METHODS Rats with obesity received daily s.c. administrations for 56 days, and glucose tolerance was assessed after one acute injection, […]
The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity.
August 1, 2016
Obesity (Silver Spring)